Drug news
Gilead Sciences files cobicistat"booster" for AIDS drugs
Gilead Sciences, announced it has submitted a New Drug Application (NDA) to the FDA for marketing approval of cobicistat, a pharmacoenhancing or �boosting� agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing. Cobicistat is also a component of the Quad once-daily single tablet regimen for HIV, which is currently under U.S. and European regulatory review for treatment-na�ve adult patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins